TIS 0.00% 0.0¢ tissue therapies limited

I have no idea how high the share price will go. However, I have...

  1. 63 Posts.
    I have no idea how high the share price will go. However, I have done some fairly simple NPV analysis based on Mercer's statement at the Spotlight Conference. Feel free to pick apart. My view is that any regulatory risk disappears and the risk that remains becomes execution risk...can our sales force hit the targets that have been put out there.

    Given that there is US sales potential not included in this analysis, as well as other commercial applications for the product, there should be upside to the valuation.

    Assumptions: Sales Margin 75%. Head office costs go up at $7m per year and then increase with sales growth from 2020. Sales growth beyond 2020 is what it was from 2020 over 2019. Anyway, here is what I get:

    Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8
    0 Revenue $m Growth % Net Revenue $M Head Office Costs $m EBIT $m NPV $m Discount Rate 10%
    1 2014 2.6 1.95 7.00 -5.05 -5.05 Exchange Rate 0.91
    2 2015 33.6 1192% 25.2 14.00 11.2 10.18182
    3 2016 96 186% 72 21.00 51 42.14876
    4 2017 267 178% 200.25 28.00 172.25 129.414
    5 2018 385 44% 288.75 35.00 253.75 173.3147
    6 2019 450 17% 337.5 42.00 295.5 183.4823
    7 2020 521 16% 390.75 49.00 341.75 192.909
    8 2021 603.2022 16% 452.4016667 56.73 395.670556 203.0416
    9 2022 698.3741 16% 523.7805963 65.68 458.098577 213.7064
    10 2023 808.562 16% 606.4215348 76.05 530.376352 224.9313
    11 2024 936.1352 16% 702.101377 88.04 614.057954 236.7459
    12 NPV USD 1604.826
    13 NPV AUD 1763.545
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.